Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
about
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus.Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
P2860
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Current Status of Bruton's Tyr ...... nd Use in B-Cell Malignancies.
@en
Current Status of Bruton's Tyr ...... nd Use in B-Cell Malignancies.
@nl
type
label
Current Status of Bruton's Tyr ...... nd Use in B-Cell Malignancies.
@en
Current Status of Bruton's Tyr ...... nd Use in B-Cell Malignancies.
@nl
prefLabel
Current Status of Bruton's Tyr ...... nd Use in B-Cell Malignancies.
@en
Current Status of Bruton's Tyr ...... nd Use in B-Cell Malignancies.
@nl
P2860
P1433
P1476
Current Status of Bruton's Tyr ...... nd Use in B-Cell Malignancies.
@en
P2093
Jennifer R Brown
P2860
P2888
P304
P356
10.1007/S40266-017-0468-4
P577
2017-05-23T00:00:00Z